The FDA has approved Fujifilm Kyowa Kirin Biologics's Hulio adalimumab biosimilar, making it the sixth adalimumab biosimilar approved in the United States. However, none will be launched before 2023 because of the strength of AbbVie's exclusivity rights for Humira, the reference product. Hulio launched in Europe in 2018.
The FDA has approved an adalimumab biosimilar (Hulio) from Fujifilm Kyowa Kirin Biologics, making it the sixth adalimumab biosimilar to AbbVie’s reference product Humira that has been approved and the 28th biosimilar approved by the FDA. Mylan will handle the commercialization in the United States.
AbbVie has contracted with all 6 adalimumab biosimilar developers for sequential launch dates, with Fujifilm Kyowa Kirin Biologics’s being July 31, 2023. The earliest would be Amgen’s on January 31, 2023.
Hulio is a tumor necrosis factor blocker indicated for the subcutaneous treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis. The injectable is available in prefilled single-dose pens at 40 mg/0.8 mL and in prefilled plastic syringes at the same dose or at 20 mg/0.4 mL.
Although only just approved in the United States, Hulio was launched across major European markets in October 2018, just 1 month after the European Commission (EC) issued a positive opinion for commercialization. At the time, Mylan indicated that the product launch was a significant milestone for its progress in developing a portfolio of biosimilar products. In partnership with other pharmaceutical companies, Mylan has marketed biosimilars in dermatology, diabetes, immunology, oncology, and ophthalmology.
The EC approval for Hulio applied to all 28 EU countries as well as the European Economic Area member states of Norway, Iceland, and Liechtenstein.
In the United States, the field of adalimumab biosimilars has been growing steadily and now represents the largest group of biosimilars approved for a single drug. Only trastuzumab comes close, with 5 biosimilars approved and launched. There are currently 17 biosimilars available for use or commercialized in the United States.
AbbVie’s list of patents protecting Humira numbers over 100 and has represented a formidable obstacle to biosimilar developers seeking to bring competitor adalimumab products to market in the United States. This accounts for the 2023 launch dates, enabling AbbVie to continue capitalizing on having exclusive distribution rights in the United States for what has been the world’s most profitable drug. Humira notched revenues of over $19 billion in 2019.
Two recent studies of Hulio provided evidence that the drug is equivalent to Humira for treating rheumatoid arthritis and confirmed the subcutaneous delivery method.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.